Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New study reveals key to more effective antihistamines

Even if two molecules have the exact same chemical formula and the same number and types of bonds, their three-dimensional arrangements can still be different.

1 Jul 2024

Moffitt scientists develop breakthrough method for scalable synthesis of withanolides

Withanolides, a class of naturally occurring compounds found in plants, have long been a focus of cancer research due to their ability to inhibit cancer cell growth, induce cell death and prevent metastasis.

28 Jun 2024

New method developed to map mechanistic connections between diseases

Tampere University researchers developed a method to map mechanistic connections between diseases, revealing deeper associations beyond traditional classifications based on affected organs and symptoms.

28 Jun 2024

Discovery of nanoparticle-based drug delivery system could revolutionize schizophrenia treatment

Schizophrenia is a complicated mental health disorder accompanied by wide range of symptoms such as hallucinations, impaired cognitive ability, and disorganized speech or behavior.

27 Jun 2024

CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team

Key appointment to support continued UK and US team expansion.

From CN Bio 27 Jun 2024

ELRIG UK and The Protein Society Partner to advance protein sciences in drug discovery

Partners to host joint conference on ‘Protein Sciences in Drug Discovery’ in Cambridge, UK from 18–19 November 2024.

From ELRIG (UK) Ltd. 26 Jun 2024

Study uncovers new insights into the main human cold and menthol sensor TRPM8

Chronic pain affects millions worldwide, and current treatments often rely on opioids, which carry risks of addiction and overdose.

21 Jun 2024

Transforming drug discovery with AI

A new AI-powered program will allow researchers to level up their drug discovery efforts.

21 Jun 2024

Insilico Medicine leadership team shares insights on AI-powered healthcare innovation

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announces that the co-CEOs of the company – Alex Zhavoronkov, PhD, and Feng Ren, PhD – will be attending the 15th Annual Meeting of the New Champions, also known as Summer Davos hosted by the World Economic Forum, in Dalian, China, from 25 to 27 June 2024.

21 Jun 2024

New insights into signaling pathways and resistance mechanisms in colorectal cancer

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The complexity of its pathogenesis, involving genetic mutations, dysregulated signaling pathways, and compromised immune surveillance, presents significant challenges for effective treatment.

21 Jun 2024

Breakthrough in enzyme communication could pave the way for new drugs

A mechanism that could help scientists harness enzymes for use in drug discovery has been discovered in a research breakthrough at the University of Birmingham.

20 Jun 2024

WEHI spinout aims to revolutionize the development of cancer drugs

Australia has cemented its role in becoming a major player in the next generation of medicines with the launch of Ternarx – a globally competitive biotechnology company dedicated to finding new treatments for hard-to-treat cancers.

20 Jun 2024

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system.

20 Jun 2024

Novel AI tool poised to reshape virtual screening in early stage drug discovery

Australian researchers, led by Monash University, have invented a new artificial intelligence (AI) tool which is poised to reshape virtual screening in early stage drug discovery and enhance scientists’ ability to identify potential new medicines.

19 Jun 2024

CCDC leverages computing power of Intel and AWS for advancement in drug discovery

Thanks to the combined computing power of Amazon Web Services (AWS) and Intel, the CCDC announces that a potentially significant advancement in drug discovery has been achieved.

18 Jun 2024

Interdisciplinary team reveals how Porphyromonas gingivalis interferes with chemotherapy-induced mitophagy

A new paper from an interdisciplinary team at MUSC Hollings Cancer Center describes how the bacteria Porphyromonas gingivalis interferes with chemotherapy-induced mitophagy, allowing oral cancer tumors to become resistant to the drug's effects.

18 Jun 2024

INTEGRA Biosciences announces the appointment of a new board member

INTEGRA Biosciences is excited to welcome Line Stigen Raquet as a non-executive board member.

From INTEGRA Biosciences 17 Jun 2024

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset.

From Enterprise Therapeutics Ltd 17 Jun 2024

Release of Unity 2.0: Order, track, and manage your compound collection through one platform

eMolecules has launched a new updated platform that enables medicinal chemists or compound managers to order, track, and manage their compound collection and commercial sources through a more intuitive and flexible system: Unity.

From eMolecules 13 Jun 2024

Open-ILD: Pioneering stem cell research to combat interstitial lung disease

Imagine a world where breathing is a luxury and a cough marks the sound of an inner battle. Interstitial Lung Disease (ILD), a condition characterised by inflammation and fibrosis, is a major cause of severe respiratory illness and can occur in children.

13 Jun 2024

Drug Discovery News and Research

Further Reading

New study reveals key to more effective antihistamines

Moffitt scientists develop breakthrough method for scalable synthesis of withanolides

New method developed to map mechanistic connections between diseases

Discovery of nanoparticle-based drug delivery system could revolutionize schizophrenia treatment

CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team

ELRIG UK and The Protein Society Partner to advance protein sciences in drug discovery

Study uncovers new insights into the main human cold and menthol sensor TRPM8

Transforming drug discovery with AI

Insilico Medicine leadership team shares insights on AI-powered healthcare innovation

New insights into signaling pathways and resistance mechanisms in colorectal cancer

Breakthrough in enzyme communication could pave the way for new drugs

WEHI spinout aims to revolutionize the development of cancer drugs

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Novel AI tool poised to reshape virtual screening in early stage drug discovery

CCDC leverages computing power of Intel and AWS for advancement in drug discovery

Interdisciplinary team reveals how Porphyromonas gingivalis interferes with chemotherapy-induced mitophagy

INTEGRA Biosciences announces the appointment of a new board member

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

Release of Unity 2.0: Order, track, and manage your compound collection through one platform

Open-ILD: Pioneering stem cell research to combat interstitial lung disease

Pharmaron’s drug conjugates platform from idea to XDC eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®